Before You Start Glp-1S: the Complete Patient Preparation and Expectations Guide
GLP-1 medications demand patience during the early weeks. The dosage titration schedule is engineered around pharmacokinetics and digestive tolerance rather than immediate weight reduction. Jumping straight to therapeutic doses triggers severe nausea, dehydration, and cyclical vomiting.
The initial four weeks serve primarily as a biological tolerance test. Most patients shed two to five pounds in the initial fortnight, primarily driven by glycogen depletion and systemic systemic inflammation reduction. Actual adipose breakdown accelerates as patients step up into intermediate doses.
| Phase & Timeline | Dosing Benchmarks (Semaglutide / Tirzepatide) | Physiological Milestones |
|---|---|---|
| Initiation (Weeks 1, 4) | 0.25 mg / 2.5 mg weekly | Delayed gastric emptying begins; water weight loss; mild nausea or bowel irregularity. |
| Escalation (Weeks 5, 12) | 0.5, 1.0 mg / 5.0, 7.5 mg weekly | Clear appetite suppression; active visceral fat loss begins; caloric intake drops by 25, 35%. |
| Therapeutic Target (Weeks 13, 24) | 1.7, 2.4 mg / 10.0, 15.0 mg weekly | Peak fat oxidation rates; profound reductions in waist circumference; heightened risk of muscle wasting if unchecked. |
| Consolidation (Weeks 25, 52+) | 2.4 mg maximum / 15.0 mg maximum | Metabolic plateau emergence; set-point stabilization; transition toward long-term maintenance. |
Between weeks 12 and 24, tirzepatide transformations often show broader shifts than semaglutide because the dual agonist targets both GIP and GLP-1 receptors. Yet individual biological variation remains vast. Some patients respond hyper-sensitively at intermediate doses, while others do not observe meaningful adipose reduction until reaching maximum therapeutic thresholds.
